Burns

Where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?

Gerd G. Gauglitz, Felicia N. Williams, David Herndon, Marc G. Jeschke

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose of Review: The hypermetabolic response in critically ill patients is characterized by hyperdynamic circulatory, physiologic, catabolic and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and death. Attenuation of the hypermetabolic response by various pharmacologic modalities is emerging as an essential component of the management of severe burn patients. This review focuses on the more recent advances in therapeutic strategies to attenuate the hypermetabolic response and its associated insulin resistance postburn. Recent Findings: At present, beta-adrenergic blockade with propranolol represents probably the most efficacious anticatabolic therapy in the treatment of burns. Other pharmacological strategies include growth hormone, insulin-like growth factor, oxandrolone and intensive insulin therapy. Summary: Novel approaches to the management of critical illness by judicious glucose control and the use of pharmacologic modulators to the hypercatabolic response to critical illness have emerged. Investigation of alternative strategies, including the use of metformin, glucagon-like-peptide-1 and the PPAR-γ agonists are under current investigation.

Original languageEnglish (US)
Pages (from-to)176-181
Number of pages6
JournalCurrent Opinion in Clinical Nutrition and Metabolic Care
Volume14
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Oxandrolone
Incretins
Human Growth Hormone
Burns
Critical Illness
Propranolol
Growth Hormone
Peroxisome Proliferator-Activated Receptors
Glucagon-Like Peptide 1
Metformin
Somatomedins
Therapeutics
Cardiovascular System
Adrenergic Agents
Insulin Resistance
Immune System
Pharmacology
Insulin
Glucose
Infection

Keywords

  • critical illness
  • glucose
  • nutrition
  • propranolol

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Burns : Where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs? / Gauglitz, Gerd G.; Williams, Felicia N.; Herndon, David; Jeschke, Marc G.

In: Current Opinion in Clinical Nutrition and Metabolic Care, Vol. 14, No. 2, 03.2011, p. 176-181.

Research output: Contribution to journalArticle

Gauglitz, Gerd G. ; Williams, Felicia N. ; Herndon, David ; Jeschke, Marc G. / Burns : Where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?. In: Current Opinion in Clinical Nutrition and Metabolic Care. 2011 ; Vol. 14, No. 2. pp. 176-181.
@article{2b96f451bdfd4dbdba1c812666f49e76,
title = "Burns: Where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?",
abstract = "Purpose of Review: The hypermetabolic response in critically ill patients is characterized by hyperdynamic circulatory, physiologic, catabolic and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and death. Attenuation of the hypermetabolic response by various pharmacologic modalities is emerging as an essential component of the management of severe burn patients. This review focuses on the more recent advances in therapeutic strategies to attenuate the hypermetabolic response and its associated insulin resistance postburn. Recent Findings: At present, beta-adrenergic blockade with propranolol represents probably the most efficacious anticatabolic therapy in the treatment of burns. Other pharmacological strategies include growth hormone, insulin-like growth factor, oxandrolone and intensive insulin therapy. Summary: Novel approaches to the management of critical illness by judicious glucose control and the use of pharmacologic modulators to the hypercatabolic response to critical illness have emerged. Investigation of alternative strategies, including the use of metformin, glucagon-like-peptide-1 and the PPAR-γ agonists are under current investigation.",
keywords = "critical illness, glucose, nutrition, propranolol",
author = "Gauglitz, {Gerd G.} and Williams, {Felicia N.} and David Herndon and Jeschke, {Marc G.}",
year = "2011",
month = "3",
doi = "10.1097/MCO.0b013e3283428df1",
language = "English (US)",
volume = "14",
pages = "176--181",
journal = "Current Opinion in Clinical Nutrition and Metabolic Care",
issn = "1363-1950",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Burns

T2 - Where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?

AU - Gauglitz, Gerd G.

AU - Williams, Felicia N.

AU - Herndon, David

AU - Jeschke, Marc G.

PY - 2011/3

Y1 - 2011/3

N2 - Purpose of Review: The hypermetabolic response in critically ill patients is characterized by hyperdynamic circulatory, physiologic, catabolic and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and death. Attenuation of the hypermetabolic response by various pharmacologic modalities is emerging as an essential component of the management of severe burn patients. This review focuses on the more recent advances in therapeutic strategies to attenuate the hypermetabolic response and its associated insulin resistance postburn. Recent Findings: At present, beta-adrenergic blockade with propranolol represents probably the most efficacious anticatabolic therapy in the treatment of burns. Other pharmacological strategies include growth hormone, insulin-like growth factor, oxandrolone and intensive insulin therapy. Summary: Novel approaches to the management of critical illness by judicious glucose control and the use of pharmacologic modulators to the hypercatabolic response to critical illness have emerged. Investigation of alternative strategies, including the use of metformin, glucagon-like-peptide-1 and the PPAR-γ agonists are under current investigation.

AB - Purpose of Review: The hypermetabolic response in critically ill patients is characterized by hyperdynamic circulatory, physiologic, catabolic and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and death. Attenuation of the hypermetabolic response by various pharmacologic modalities is emerging as an essential component of the management of severe burn patients. This review focuses on the more recent advances in therapeutic strategies to attenuate the hypermetabolic response and its associated insulin resistance postburn. Recent Findings: At present, beta-adrenergic blockade with propranolol represents probably the most efficacious anticatabolic therapy in the treatment of burns. Other pharmacological strategies include growth hormone, insulin-like growth factor, oxandrolone and intensive insulin therapy. Summary: Novel approaches to the management of critical illness by judicious glucose control and the use of pharmacologic modulators to the hypercatabolic response to critical illness have emerged. Investigation of alternative strategies, including the use of metformin, glucagon-like-peptide-1 and the PPAR-γ agonists are under current investigation.

KW - critical illness

KW - glucose

KW - nutrition

KW - propranolol

UR - http://www.scopus.com/inward/record.url?scp=79952039952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952039952&partnerID=8YFLogxK

U2 - 10.1097/MCO.0b013e3283428df1

DO - 10.1097/MCO.0b013e3283428df1

M3 - Article

VL - 14

SP - 176

EP - 181

JO - Current Opinion in Clinical Nutrition and Metabolic Care

JF - Current Opinion in Clinical Nutrition and Metabolic Care

SN - 1363-1950

IS - 2

ER -